Drug Trial Radar · NCT06699212
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
Last checked: Nov 20, 2026Latest source record: Oct 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
412
Planned (sponsor's estimate)
Start
Dec 24, 2024
Primary completion
Sep 2028
Study completion Sep 2028
Sponsor
- Lead sponsor
- Rakuten Medical, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn about the safety of ASP-1929 PIT in combination with pembrolizumab. Researchers will compare ASP-1929 PIT in combination with pembrolizumab to pembrolizumab alone or pembrolizumab plus chemotherapy (carboplatin or cisplatin, plus 5-fluorouracil or paclitaxel or docetaxel) according to physician's choice (control arm). The overall primary study hypothesis being tested is whether ASP-1929 PIT plus pembrolizumab combination treatment improves the overall survival (OS) of the population defined by the inclusion/exclusion criteria over the control arm.
Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
ASP-1929 PhotoimmunotherapyCombination product
ASP-1929 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion (up to 24 months)
PembrolizumabBiological
200 mg Q3W or 400 mg Q6W, IV infusion over 30 minutes (up to 24 months)
CarboplatinDrug
Area under the curve (AUC) 5 mg/mL/min IV infusion, Q3W up to 6 cycles
CisplatinDrug
100 mg/m\^2 IV infusion, Q3W up to 6 cycles
5-fluorouracilDrug
1000 mg/m\^2 per day from Days 1-4 of each cycle, IV infusion, Q3W up to 6 cycles
PaclitaxelDrug
100 mg/m\^2 IV infusion given on Days 1 and 8, Q3W up to 6 cycles or 175 mg/m\^2 IV infusion given on Day 1, Q3W up to 6 cycles
DocetaxelDrug
75 mg/m\^2 IV Infusion, Q3W up to 6 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Up to approximately 48 months
Locations
22 sites in 3 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
University of Miami
Miami, Florida · Recruiting
Tampa General Hospital
Tampa, Florida · Recruiting
University of Kentucky Medical Center
Lexington, Kentucky · Withdrawn
Thomas Jefferson University, Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania · Recruiting
Rhode Island Hospital
Providence, Rhode Island · Recruiting
Avera Cancer Institute
Sioux Falls, South Dakota · Recruiting
University of Texas, MD Anderson Cancer Center
Houston, Texas · Recruiting
Aichi Cancer Center
Aichi, Japan · Recruiting
Hiroshima University Hospital
Hiroshima, Japan · Recruiting
Kyoto Prefectural University of Medicine
Kyoto, Japan · Recruiting
Tokyo Medical University Hospital
Tokyo, Japan · Recruiting
Tottori University Hospital
Yonago, Japan · Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan · Recruiting
China Medical University
Taichung, Taiwan · Recruiting
Taichung Veterans General Hospital
Taichung, Taiwan · Recruiting
Chi Mei Hospital
Tainan, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
MacKay Memorial Hospital
Taipei, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Taipei Municipal Wanfang Hospital
Taipei, Taiwan · Recruiting
Linkou Chang Gung Memorial Hospital
Taoyuan City, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.